Tvardi Therapeutics (NASDAQ:TVRD) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a report published on Saturday.

Other research analysts also recently issued reports about the stock. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. BTIG Research reissued a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $55.50.

Tvardi Therapeutics Stock Down 1.3%

NASDAQ:TVRD opened at $2.98 on Friday. The company has a fifty day moving average of $3.68 and a 200 day moving average of $8.06. Tvardi Therapeutics has a 52 week low of $2.81 and a 52 week high of $43.65. The firm has a market capitalization of $27.95 million, a P/E ratio of -0.53 and a beta of 0.16.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23).

Institutional Trading of Tvardi Therapeutics

Several institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $80,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Finally, Arax Advisory Partners grew its position in Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after purchasing an additional 6,173 shares during the last quarter. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.